PENPenumbra Inc
Company Overview
Name
52W High
52W Low
Market Cap
Dividend Yield
Price/earnings
P/E
Dividends
No dividend
Sentiment
Score
Bullish
63
Low
Neutral
High
0
50
100
Trade Volume
Score
Neutral
50
Low
Neutral
High
0
50
100
Income Statement
Total Revenue
Operating Revenue
Total Gross Profit
Total Operating Income
Net Income
EV to EBITDA
EV to Revenue
Price to Book value
Price to Earnings
Additional Data
Selling, General & Admin Expense
Research & Development Expense
Total Operating Expenses
Total Costs & Expenses
Interest & Investment Income
Total Other Income / (Expense), net
Earnings History
- Estimated
- Reported, beat
- Reported, missed
Estimated EPS
Reported EPS
N/ACompany Overview
Name
52W High
52W Low
Market Cap
Dividend Yield
Price/earnings
P/E
Dividends
No dividend
Sentiment
Score
Bullish
63
Low
Neutral
High
0
50
100
Trade Volume
Score
Neutral
50
Low
Neutral
High
0
50
100
Income Statement
Total Revenue
Operating Revenue
Total Gross Profit
Total Operating Income
Net Income
EV to EBITDA
EV to Revenue
Price to Book value
Price to Earnings
Additional Data
Selling, General & Admin Expense
Research & Development Expense
Total Operating Expenses
Total Costs & Expenses
Interest & Investment Income
Total Other Income / (Expense), net
Earnings History
- Estimated
- Reported, beat
- Reported, missed
Estimated EPS
Reported EPS
N/AUpcoming Earnings
Company Info
CEO
Adam Elsesser
Location
California, USA
Exchange
NYSE
Website
https://penumbrainc.com
Summary
Penumbra, Inc.
Company Info
CEO
Adam Elsesser
Location
California, USA
Exchange
NYSE
Website
https://penumbrainc.com
Summary
Penumbra, Inc.
Community Research
Research from investors like you
Be the first to share your analysis on PEN
Help fellow investors make informed decisions by sharing your research on fundamentals, catalysts, and outlook.
Symbol's posts
Boston Scientific Raises Billions to Finance Its Big Penumbra Acquisition
Boston Scientific Raises Billions to Finance Its Big Penumbra Acquisition
Boston Scientific is making a major move in the debt market, pricing $3 billion in US dollar-denominated senior notes alongside another €4.25 billion in euro-denominated notes.
The bigger story is where that money is going. The company plans to use the proceeds, along with cash and additional borrowing, to help finance its proposed acquisition of Penumbra . The deal was valued at approximately $14.5 billion when announced.
What caught my attention is the scale of the financing. Boston Scientific is taking on a substantial funding commitment to expand its medical technology business, and the acquisition could strengthen its position in areas such as vascular and neurovascular treatments.
But there’s a risk investors shouldn’t overlook. More borrowing means additional interest costs, and the company will need to make sure the acquisition delivers enough long-term value to justify the investment.
Personally, I see the strategic opportunity, but execution and debt management will be just as important as the deal itself.
Do you think the Penumbra acquisition will be worth the financial commitment for Boston Scientific, or is the company taking on too much debt?
Market recap: TSMC and banks lead recovery, oil drops 4%
Market recap: TSMC and banks lead recovery, oil drops 4%
finance.yahoo.com
| Stock market today: Dow, S&P 500, Nasdaq rise as TSMC boosts AI hopes, bank stocks rally
No more topics to show
